Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: A'Hern, R. P., Smith, I. E., Ebbs, S. R.
Formato: Artigo
Idioma:English
Publicado em: Nature Publishing Group 1993
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1968345/
https://ncbi.nlm.nih.gov/pubmed/8471439
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
id pubmed-1968345
record_format dspace
spelling pubmed-19683452009-09-10 Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. A'Hern, R. P. Smith, I. E. Ebbs, S. R. Br J Cancer Research Article The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens in which dox was replaced by one or more compounds. Trials were selected which published data on survival, time to treatment failure and response rate. This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox. Nature Publishing Group 1993-04 /pmc/articles/PMC1968345/ /pubmed/8471439 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
institution US National Library of Medicine
collection PubMed Central
language English
format Article
topic Research Article
spellingShingle Research Article
A'Hern, R. P.
Smith, I. E.
Ebbs, S. R.
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
description The value of the inclusion of doxorubicin hydrochloride (dox) in Cooper type regimens in advanced breast cancer was assessed by performing an overview employing summary statistics derived from published papers of randomised clinical trials comparing Cooper type regimens that contain dox with regimens in which dox was replaced by one or more compounds. Trials were selected which published data on survival, time to treatment failure and response rate. This study suggests that dox confers advantages on all of these endpoints and that the size of such benefits needs to be taken into account when deciding whether to use dox.
author A'Hern, R. P.
Smith, I. E.
Ebbs, S. R.
author_facet A'Hern, R. P.
Smith, I. E.
Ebbs, S. R.
author_sort A'Hern, R. P.
title Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
title_short Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
title_full Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
title_fullStr Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
title_full_unstemmed Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
title_sort chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in cooper type regimens.
publisher Nature Publishing Group
publisher_facet Nature Publishing Group
publishDate 1993
url https://ncbi.nlm.nih.gov/pmc/articles/PMC1968345/
https://ncbi.nlm.nih.gov/pubmed/8471439
_version_ 1760492313194266624

Registos relacionados